e Company. Such statements may be identified by the use of words like "plan," "expect," "aim," "believe," "project," "anticipate," "commit," "intend," "estimate," "will," "should," "could," "potential" and other expressions that indicate future events and trends.
All statements that address expectations or projections about the future, including without limitation, statements about product development, product launches, regulatory approvals, governmental and regulatory actions and proceedings, market position, acquisitions, sale of assets, revenues, expenditures, resumption of manufacturing and distribution of products and the impact of the recall and suspension of shipments on revenues, and other financial results, are forward-looking statements.
All forward-looking statements are based on current expectations and are subject to risk and uncertainties. In connection with the PSLRA's "safe harbor" provisions, the Company provides the following cautionary statements identifying important economic, competitive, political, regulatory and technological factors, among others, that could cause actual results or events to differ materially from those set forth or implied by the forward-looking statements and related assumptions.
Such factors include (but are not limited to) the following:
- our ability to continue as a going concern;
- the impact of competitive, commercial, payor, governmental, physician, patient, public or political responses and reactions, and responses and reactions by medical professional associations and advocacy groups, to the Company’s sales, marketing, product pricing, product access and strategic efforts with respect to Makena™, and its other products, including introduction or potential introduction of generic or competing products, or competition from unapproved therapies or compounded drugs, against products sold by the Company and its subsidiaries, includi
Page: 1 2 3 4 5 6 7 Related biology technology :1
|SOURCE K-V Pharmaceutical Company|
Copyright©2010 PR Newswire.
All rights reserved
. Keryx Biopharmaceuticals, Inc. to Hold Conference Call on Second Quarter 2008 Financial Results on Monday, August 11, at 8:30 A.M. EDT2
. Par Pharmaceutical Reports Second Quarter 2008 Results3
. ISTA Pharmaceuticals Reports Second Quarter 2008 Financial Results4
. SGX Pharmaceuticals Announces Financial Results for the Three and Six Months Ended June 30, 20085
. ADVENTRX Pharmaceuticals to Report Second Quarter 2008 Results6
. Huifeng Bio-Pharmaceutical (HFGB) Announces USD $1.1 Million Supply Agreement with DNP International Co. Inc.7
. Merrimack Pharmaceuticals Initiates Enrollment in a Phase 1 Study of MM-121, an ErbB3 Antagonist8
. VIA Pharmaceuticals to Present at Fourth Annual Noble Financial Equity Conference9
. Anthera Pharmaceuticals Completes $19 Million Financing; Appoints Christopher S. Henney as Chairman10
. Access Pharmaceuticals to Present at the Noble Financial Equity Conference11
. Indevus Pharmaceuticals Announces Issuance of U.S. Patent for SANCTURA XR(TM)